NCT05075538 - COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

January 8, 2024

Study Completion Date

January 8, 2024

Conditions

Cancer

Interventions

BIOLOGICAL

Spikevax

Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.

BIOLOGICAL

Comirnaty

Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.

BIOLOGICAL

Spikevax bivalent Original/Omicron BA.1

Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.

BIOLOGICAL

Spikevax bivalent Original/Omicron BA.4-5

Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.

BIOLOGICAL

Comirnaty Original/Omicron BA.1

Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.

BIOLOGICAL

Comirnaty Original/Omicron BA.4-5

Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.

BIOLOGICAL

Comirnaty Omicron XBB.1.5

Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.

BIOLOGICAL

Spikevax Omicron XBB.1.5

Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.

Trial Locations (2)

Institut Jules Bordet, Anderlecht

CHU UCL Namur Sainte-Elisabeth, Namur